Inorganic phosphate ion (Pi)

Inorganic phosphate in the gastrointestinal lumen is a primary target for pharmacological intervention in patients with chronic kidney disease (CKD). Under normal physiological conditions, phosphate is absorbed from the diet through both paracellular diffusion and active transport mediated by sodium-phosphate cotransporters [1, 2]. In the context of renal failure, the body's ability to excrete phosphate is compromised, leading to hyperphosphatemia, which is a major driver of cardiovascular morbidity and mineral bone disorders [3]. Therapeutic strategies focus on the sequestration of these inorganic phosphate ions within the gut to prevent their entry into the bloodstream. Phosphate binders, such as sevelamer and various metal salts, are used to chemically bind the phosphate ions in the lumen, forming insoluble compounds that are subsequently excreted in the feces [1, 4]. By reducing the bioavailability of phosphate, these interventions help maintain serum phosphorus levels within a safe range and mitigate the long-term complications of mineral imbalance [2, 3]. This approach is essential for controlling secondary hyperparathyroidism and reducing the risk of ectopic calcification in the vasculature [1, 4].

Other names

PhosphateOrthophosphatePO4(3-)Gastrointestinal phosphateLuminal phosphate

Phosphate binders act by chelating or binding to inorganic phosphate ions within the gastrointestinal lumen to form insoluble complexes, which are then excreted in the feces, thereby preventing systemic absorption.